RESUMO
The paper describes a procedure for manufacturing the new anthelminthic Tizanox. It shows it necessary to administer a larger dose of the drug than that of azinox (praziquantel) to treat experimental hymenolepiasis. However, the lower toxicity of Tizanox enhances its chemotherapeutical index.
Assuntos
Anticestoides/síntese química , Anticestoides/uso terapêutico , Himenolepíase/tratamento farmacológico , Isoquinolinas/síntese química , Isoquinolinas/uso terapêutico , Tiadiazinas/síntese química , Tiadiazinas/uso terapêutico , Animais , Anticestoides/análise , Anticestoides/toxicidade , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Isoquinolinas/análise , Isoquinolinas/toxicidade , Camundongos , Praziquantel/análogos & derivados , Praziquantel/uso terapêutico , Praziquantel/toxicidade , Espectrofotometria Infravermelho/estatística & dados numéricos , Tiadiazinas/análise , Tiadiazinas/toxicidadeRESUMO
The paper outlines a procedure for manufacturing the anthelminthic Azinox (biltricide) using the new interfacial transfer catalyst benzyl-di-propyl (beta-hydroxyethyl)ammonium chloride. Azinox has been shown to be identical to biltricide (praziquantel) in its properties. Azinox tests on models of Opisthorchis felineus in golden hamsters and of Hymenolepis nana in albino outbred mice have indicated that the agent is not inferior to biltricide in its antitrematodal and anticestodal activities. Azinox displayed a high activity at the preimaginal stages of O. felineus and H. nana and at the larval stage of H.nana.
Assuntos
Anticestoides/síntese química , Antiplatelmínticos/síntese química , Praziquantel/análogos & derivados , Animais , Anticestoides/uso terapêutico , Anticestoides/toxicidade , Antiplatelmínticos/uso terapêutico , Antiplatelmínticos/toxicidade , Cricetinae , Avaliação Pré-Clínica de Medicamentos , Feminino , Himenolepíase/tratamento farmacológico , Himenolepíase/parasitologia , Dose Letal Mediana , Masculino , Mesocricetus , Camundongos , Opistorquíase/tratamento farmacológico , Opistorquíase/parasitologia , Praziquantel/síntese química , Praziquantel/uso terapêutico , Praziquantel/toxicidadeRESUMO
A synthesis is described and the results of toxicological trial of the potential anthelmintic agent G-1587 are presented. The agent is 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-2H-[1, 2,5] thiadiazino [3,2-a] isoquinoline-4,4-dioxide. The agent was shown to have a low toxicity, the maximal sublethal dose for mice being 4.0 g/kg when given per os.
Assuntos
Anticestoides/toxicidade , Isoquinolinas/toxicidade , Praziquantel/análogos & derivados , Tiadiazinas/toxicidade , Animais , Anticestoides/uso terapêutico , Cricetinae , Avaliação Pré-Clínica de Medicamentos , Equinococose/tratamento farmacológico , Feminino , Himenolepíase/tratamento farmacológico , Isoquinolinas/uso terapêutico , Dose Letal Mediana , Masculino , Mesocricetus , Camundongos , Praziquantel/uso terapêutico , Praziquantel/toxicidade , Tiadiazinas/uso terapêuticoRESUMO
The toxicity and anthelminthic activity of the earlier synthetized tricyclic analogues of praziquantel and 4-acylpiperazinones-2 have been studied. Tricyclic compounds have shown the acute toxicity similar to that of praziquantel and neurotoxic effect typical of praziquantel. 4-acylpiperazinones-2 toxicity correlated with their anthelminthic effect. The determination of anthelminthic activity of the above compounds in opisthorchiasis and hymenolepiasis has shown that they are less effective than praziquantel or have no anthelminthic activity. A biological activity-structure relationship has been traced in the compounds under study.